Provided by Tiger Trade Technology Pte. Ltd.

Madrigal Pharmaceuticals

510.60
-6.1450-1.19%
Volume:29.11K
Turnover:14.87M
Market Cap:11.77B
PE:-35.92
High:517.00
Open:517.00
Low:507.18
Close:516.74
52wk High:615.00
52wk Low:393.61
Shares:23.06M
Float Shares:13.73M
Volume Ratio:0.35
T/O Rate:0.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.2164
EPS(LYR):-12.8501
ROE:-53.31%
ROA:-17.84%
PB:22.48
PE(LYR):-39.73

Loading ...

How Blockbuster Rezdiffra Sales and ARO‑PNPLA3 Licensing Will Impact Madrigal Pharmaceuticals (MDGL) Investors

Simply Wall St.
·
May 09

Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays

TIPRANKS
·
May 08

Madrigal grants inducement equity awards to 47 new employees under 2025 plan

Reuters
·
May 08

Madrigal Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
May 07

Truist Financial Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)

TIPRANKS
·
May 07

Madrigal Pharmaceuticals Inc : Clear Street Raises Target Price to $680 From $533

THOMSON REUTERS
·
May 07

Madrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)

TIPRANKS
·
May 07

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL) and Pennant Group (PNTG)

TIPRANKS
·
May 07

BUZZ-Madrigal Pharma rises after Q1 revenue beat

Reuters
·
May 06

Stock Track | Madrigal Pharmaceuticals Soars 7.44% in Pre-market on Strong Q1 Earnings Beat and Pipeline Expansion

Stock Track
·
May 06

Madrigal Pharmaceuticals Price Target Maintained With a $620.00/Share by HC Wainwright & Co.

Dow Jones
·
May 06

Madrigal's Q1 product revenue jumps 127%, net loss widens on higher costs

Reuters
·
May 06

Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q1 Net Loss $3.25 a Share, vs. FactSet Est of $4.23 Loss

MT Newswires Live
·
May 06

Madrigal Pharmaceuticals Q1 EPS $(3.25) Beats $(3.60) Estimate, Sales $311.337M Beat $302.268M Estimate

Benzinga Earnings
·
May 06

BRIEF-Madrigal Pharmaceuticals Q1 Product Revenue USD 311.337 Million

Reuters
·
May 06

Madrigal Pharmaceuticals Inc: Mgl-2086 (Oral Glp-1) Phase 1 Trial on Track to Initiate in 2Q26

THOMSON REUTERS
·
May 06

Madrigal Pharmaceuticals Q1 EPS USD 3.25

THOMSON REUTERS
·
May 06

Madrigal Pharmaceuticals Q1 Operating Expenses USD 404.06 Million

THOMSON REUTERS
·
May 06

Madrigal Pharmaceuticals Q1 Net Income USD -94.391 Million

THOMSON REUTERS
·
May 06

Madrigal Pharmaceuticals Inc: Ervogastat/Resmetirom Drug-Drug Interaction Study on Track to Initiate in 4Q26

THOMSON REUTERS
·
May 06